



June 28, 2024

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

email: [ir@ppmx.com](mailto:ir@ppmx.com)

To all stakeholders,

**PPMX-T003: Announcement on the End of Phase I Clinical Trial  
for Polycythemia Vera (PV)**

Perseus Proteomics Inc. (The Company) hereby announces that the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients has finished.

This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects. This clinical trial was expected to finish in the end of July, when the observation period of the last patient after administration should finish, however, the test of this patient was terminated due to the patient's intension. Accordingly, the clinical trial has completed the prescribed observations and now finished. The Company has received no report of serious adverse events which raise concerns on the safety of PPMX-T003 with this patient.

There is neither impact on the financial results for the fiscal year ending March 31, 2025 nor change in the plan of licensing out in this fiscal year.

END